- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Placebo, azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 5,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- TAK-279, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
- Conditions
- Distal and Lateral Subungual Onychomycosis
- Interventions
- Luliconazole Solution, 10%, Vehicle Solution
- Drug
- Lead sponsor
- Topica Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,627 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
- Conditions
- Advanced Cutaneous Melanoma
- Interventions
- ITIL-168
- Biological
- Lead sponsor
- Instil Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 14 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Not listed
- Lead sponsor
- TearLab Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- San Diego, California • Louisville, Kentucky • Columbus, Ohio
- Conditions
- Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
- Interventions
- Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 662
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
- Conditions
- Infection
- Interventions
- 70% Isopropyl alcohol embedded caps, Usual Care
- Device · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Day to 35 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
- Conditions
- Gastrointestinal Motility
- Interventions
- PillCam
- Device
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Deep Vein Thrombosis, Post-thrombotic Syndrome
- Interventions
- EkoSonic® Endovascular System, Alteplase
- Device · Biological
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Aurora, Colorado • Darien, Connecticut + 18 more
- Conditions
- Crohn Disease
- Interventions
- certolizumab pegol (CDP870, CZP), Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 24
- States / cities
- Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more
- Conditions
- Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Months to 20 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Vincristine, Mechlorethamine, Etoposide, Prednisone, Cyclophosphamide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 517
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 329 more
- Conditions
- Tinea Pedis
- Interventions
- NAFT-600 ( naftin 2 % gel ), Placebo
- Drug
- Lead sponsor
- Merz North America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 855 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, mRNA-1283
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Overland Park, Kansas • Louisville, Kentucky • Charlotte, North Carolina + 2 more
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Interventions
- DEB-TACE, Sorafenib
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 19
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
- Conditions
- Allergic Conjunctivitis (AC)
- Interventions
- EBI-005, Placebo Comparator
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 11
- States / cities
- Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Topical roflumilast
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 68
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 58 more
- Conditions
- Facial Vascularized Composite Allotransplantation, Functional Recovery
- Interventions
- Facial Vascularized Composite Allotransplantation (VCA)
- Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2037
- U.S. locations
- 9
- States / cities
- Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more